HHS issues guidance on ordering commercial COVID-19 monoclonal antibody
The Department of Health and Human Services yesterday released new guidance on ordering, reporting, payment and cost-sharing for the COVID-19 monoclonal antibody therapy bebtelovimab, a treatment option for outpatients at high risk for hospitalization that begins transitioning from HHS to commercial distribution next week. Anticipating depletion of the federal government’s supply, Eli Lilly and Co. is making bebtelovimab available for purchase through AmerisourceBergen.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…